-
Views
-
Cite
Cite
Madelon van Wely, Neriman Bayram, Fulco van der Veen, Patrick Bossuyt, Reply to: Are laparoscopic ovarian diathermy and gonadotropin administration the only therapeutic second-steps in clomiphene-citrate resistant women with polycystic ovary syndrome?, Human Reproduction, Volume 19, Issue 11, 1 November 2004, Page 2683, https://doi.org/10.1093/humrep/deh469
Close - Share Icon Share
Extract
1Center for Reproductive Medicine, Department of Obstetrics and Gynaecology and 2Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Sir,
We would like to thank Dr Palomba and colleagues for their interest in our paper (van Wely et al., 2004). In Western Europe, recombinant FSH is most commonly used for ovulation induction in women with polycystic ovary syndrome (PCOS) that does not respond to clomiphene citrate (CC). Urinary FSH is practically not used anymore in The Netherlands. The only alternative gonadotrophin to rFSH that is available on the market is human menopausal gonadotrophin (hMG). We agree with Dr Palomba and colleagues that there is no evidence of a difference in effectiveness and safety between rFSH and hMG for this indication (van Wely et al., 2003; Bayram et al., 2004). However, we chose to compare a laparoscopic electrocautery strategy with rFSH, as ovulation induction with rFSH best represents current practice in the Netherlands.
